Your browser doesn't support javascript.
loading
Development of a cost-effective ovine antibody-based therapy against SARS-CoV-2 infection and contribution of antibodies specific to the spike subunit proteins.
Findlay-Wilson, Stephen; Easterbrook, Linda; Smith, Sandra; Pope, Neville; Humphries, Gareth; Schuhmann, Holger; Ngabo, Didier; Rayner, Emma; Otter, Ashley David; Coleman, Tom; Hicks, Bethany; Graham, Victoria Anne; Halkerston, Rachel; Apostolakis, Kostis; Taylor, Stephen; Fotheringham, Susan; Horton, Amanda; Tree, Julia Anne; Wand, Matthew; Hewson, Roger; Dowall, Stuart David.
Afiliación
  • Findlay-Wilson S; United Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
  • Easterbrook L; United Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
  • Smith S; International Therapeutic Proteins Ltd (Australia), Longford, Tasmania, 7301, Australia.
  • Pope N; International Therapeutic Proteins Ltd (UK), Goleigh Farm, Selborne, Hampshire, GU34 3SE, UK.
  • Humphries G; Native Antigen Company, Langford Locks, Kidlington, Oxford, OX5 1LH, UK.
  • Schuhmann H; Native Antigen Company, Langford Locks, Kidlington, Oxford, OX5 1LH, UK.
  • Ngabo D; United Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
  • Rayner E; United Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
  • Otter AD; United Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
  • Coleman T; United Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
  • Hicks B; United Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
  • Graham VA; United Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
  • Halkerston R; United Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
  • Apostolakis K; United Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
  • Taylor S; United Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
  • Fotheringham S; United Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
  • Horton A; United Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
  • Tree JA; United Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
  • Wand M; United Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
  • Hewson R; United Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK.
  • Dowall SD; United Kingdom Health Security Agency (UKHSA), Porton Down, Salisbury, Wiltshire, SP4 0JG, UK. Electronic address: stuart.dowall@phe.gov.uk.
Antiviral Res ; 203: 105332, 2022 07.
Article en En | MEDLINE | ID: mdl-35533779
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: COVID-19 / Tratamiento Farmacológico de COVID-19 Tipo de estudio: Health_economic_evaluation Idioma: En Revista: Antiviral Res Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: COVID-19 / Tratamiento Farmacológico de COVID-19 Tipo de estudio: Health_economic_evaluation Idioma: En Revista: Antiviral Res Año: 2022 Tipo del documento: Article